Peer-influenced content. Sources you trust. No registration required. This is HCN.

JAMA NetworkMuch Anticipated Alzheimer Disease Prevention Trial Finds No Clinical Benefit From Drug Targeting Amyloid; Highlights Need to Consider Other Approaches

The disappointing findings from the $100 million National Institutes of Health (NIH) project, the first-ever prevention trial for Alzheimer’s disease, which tested an antiamyloid monoclonal antibody called crenezumab in people with the Paisa mutation, the most common cause of familial, early-onset Alzheimer’s disease.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form